Bioassay and cGMP Potency Testing
Bioassays are essential for the development of new biopharmaceuticals. In particular, per regulatory requirement, they are performed to determine the biological activity or potency of the product, a critical quality attribute according to ICH Q6B.
Due to their complex nature, bioassays are one of the most challenging assays to perform. Therefore, consistent assay performance requires a controlled environment, skilled analysts with a thorough understanding of cell physiology and a well-developed and characterized method.
Eurofins BioPharma Product Testing offers extensive experience in all aspects of bioassay development, validation, method transfer and long-term assay maintenance. We provide a dedicated turnkey service for all your bioassay needs. The bioassay teams of Eurofins BioPharma Product Testing Munich, Germany, Dungarvan, Ireland, Columbia, MO and Lancaster, PA, work closely together to design and execute customized binding assays, cellular in vitro bioassays, as well as non-cell-based in vivo* bioassays.
Our unmatched expertise and proven track record for cGMP potency assay testing ensures successful and timely completion of your testing program.
Why Choose Eurofins BioPharma Product Testing?
- We have a success rate of greater than 95% on potency assay transfers.
- We have more experienced Ph.D.s than any other contract laboratory, including Ph.D. scientists dedicated to troubleshooting problematic assays and developing new assay platforms and methodologies.
- We perform approximately 90 potency development and transfer projects per year.
Our validation strategies are based on a sponsor’s requirements, as well as international regulatory guidelines and recommendations, such as ICH, US FDA, ISO, EMA and USP/EP. Our development, optimization (using Design of Experiments), validation and performance of bioassays and potency assays are US FDA approved and are conducted according to GMP regulations. We also offer regulatory consulting
services to support your project.
Potency Assay Experience
Our scientists have a wealth of experience performing a variety of binding and cell-based potency assays and in vivo* bioassays to support development, licensing
and commercial release of various biopharmaceutical products.
We have established and validated various sponsor-specific assays, pharmacopeia methods, as well as generic biosimilar methods, including Erythropoietin*, Filgrastim, Interferon, Etanercept, Adalimumab, Golimumab, Bevacizumab, Rituximab and Trastuzumab.
- Therapeutic antibodies (monoclonal Ab, Bi-specific Ab, Fab, antibody drug conjugate/immunoconjugate)
- Recombinant proteins (growth factors, cytokines, soluble receptors, Fc or other fusion proteins)
- Gene therapy products (viral and plasmid based)
|Substance Class||Type of Assay||Assay Readout|
|Therapeutic Antibodies||Cell Proliferation, Cell Survival,
Cell Apoptosis, Reporter Gene
Assay, Binding Assay, Cellular
Binding Assay, Cell Migration
Assay, ADCC, CDC
Fluorescence, FACS, ELISA,
|Cell Proliferation, Reporter Gene
|Antibody Drug Conjugates/
|Cell Survival, Binding Assay, Cell
|Growth Factors/Cytokines||Cell Proliferation, Viral CPE
|Peptides||Reporter Gene Assay||Luminescence|
|Soluble Receptors, FC or other
|Cellular Binding Assay, Binding
|FACS, ELISA / SPR|
|Gene Therapy Products (Viral
and Plasmid Based)
|Transfection Assay||Cell Viability / Cell Count|
Request more information to start working with us today.